JP2010528073A - 循環器疾患を画像化するためのフェニルオキシアニリン誘導体の使用 - Google Patents
循環器疾患を画像化するためのフェニルオキシアニリン誘導体の使用 Download PDFInfo
- Publication number
- JP2010528073A JP2010528073A JP2010509713A JP2010509713A JP2010528073A JP 2010528073 A JP2010528073 A JP 2010528073A JP 2010509713 A JP2010509713 A JP 2010509713A JP 2010509713 A JP2010509713 A JP 2010509713A JP 2010528073 A JP2010528073 A JP 2010528073A
- Authority
- JP
- Japan
- Prior art keywords
- heart
- alkyl group
- carbons
- disease
- radioisotope
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000024172 Cardiovascular disease Diseases 0.000 title abstract description 7
- GYNAVKULVOETAD-UHFFFAOYSA-N n-phenoxyaniline Chemical class C=1C=CC=CC=1NOC1=CC=CC=C1 GYNAVKULVOETAD-UHFFFAOYSA-N 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 15
- 230000004065 mitochondrial dysfunction Effects 0.000 claims abstract description 11
- 208000019622 heart disease Diseases 0.000 claims abstract description 10
- 230000002093 peripheral effect Effects 0.000 claims abstract description 10
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 17
- 210000002216 heart Anatomy 0.000 claims description 11
- 208000023275 Autoimmune disease Diseases 0.000 claims description 10
- 208000017169 kidney disease Diseases 0.000 claims description 9
- 206010061218 Inflammation Diseases 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 150000002367 halogens Chemical class 0.000 claims description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 8
- 230000004054 inflammatory process Effects 0.000 claims description 8
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 238000003384 imaging method Methods 0.000 claims description 7
- 208000019553 vascular disease Diseases 0.000 claims description 7
- 201000001320 Atherosclerosis Diseases 0.000 claims description 6
- 208000009525 Myocarditis Diseases 0.000 claims description 6
- 125000005843 halogen group Chemical group 0.000 claims description 6
- 210000003734 kidney Anatomy 0.000 claims description 6
- 230000002792 vascular Effects 0.000 claims description 6
- 206010019280 Heart failures Diseases 0.000 claims description 5
- 208000027866 inflammatory disease Diseases 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 206010002329 Aneurysm Diseases 0.000 claims description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 4
- 208000029078 coronary artery disease Diseases 0.000 claims description 4
- 125000001153 fluoro group Chemical group F* 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 210000004204 blood vessel Anatomy 0.000 claims description 3
- 206010014665 endocarditis Diseases 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 208000002330 Congenital Heart Defects Diseases 0.000 claims 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 claims 1
- 206010052337 Diastolic dysfunction Diseases 0.000 claims 1
- 201000010046 Dilated cardiomyopathy Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 208000028831 congenital heart disease Diseases 0.000 claims 1
- 208000027744 congestion Diseases 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 102000004300 GABA-A Receptors Human genes 0.000 abstract description 10
- 108090000839 GABA-A Receptors Proteins 0.000 abstract description 10
- 230000004913 activation Effects 0.000 abstract description 3
- 230000000747 cardiac effect Effects 0.000 abstract description 3
- 230000035778 pathophysiological process Effects 0.000 abstract description 2
- -1 2-iodoethyl group Chemical group 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 206010003210 Arteriosclerosis Diseases 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 4
- 206010052428 Wound Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 208000011775 arteriosclerosis disease Diseases 0.000 description 4
- 229910052731 fluorine Inorganic materials 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- 201000009925 nephrosclerosis Diseases 0.000 description 4
- 208000009304 Acute Kidney Injury Diseases 0.000 description 3
- 208000033626 Renal failure acute Diseases 0.000 description 3
- 201000011040 acute kidney failure Diseases 0.000 description 3
- 208000012998 acute renal failure Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- NZZFYRREKKOMAT-UHFFFAOYSA-N diiodomethane Chemical compound ICI NZZFYRREKKOMAT-UHFFFAOYSA-N 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 2
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- BQGMMFZDQBVDCE-UHFFFAOYSA-N n-(5-fluoro-2-phenoxyphenyl)-n-[(2-hydroxy-5-methoxyphenyl)methyl]acetamide Chemical compound COC1=CC=C(O)C(CN(C(C)=O)C=2C(=CC=C(F)C=2)OC=2C=CC=CC=2)=C1 BQGMMFZDQBVDCE-UHFFFAOYSA-N 0.000 description 2
- NZVKWLWAFUSDQE-FNNGWQQSSA-N n-[[2-(2-fluoranylethoxy)-5-methoxyphenyl]methyl]-n-(5-fluoro-2-phenoxyphenyl)acetamide Chemical compound COC1=CC=C(OCC[18F])C(CN(C(C)=O)C=2C(=CC=C(F)C=2)OC=2C=CC=CC=2)=C1 NZVKWLWAFUSDQE-FNNGWQQSSA-N 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- KENPFZUYYWVXNW-UHFFFAOYSA-N 2-bromoethyl trifluoromethanesulfonate Chemical compound FC(F)(F)S(=O)(=O)OCCBr KENPFZUYYWVXNW-UHFFFAOYSA-N 0.000 description 1
- XNRDLSNSMTUXBV-UHFFFAOYSA-N 2-fluoroethyl 4-methylbenzenesulfonate Chemical compound CC1=CC=C(S(=O)(=O)OCCF)C=C1 XNRDLSNSMTUXBV-UHFFFAOYSA-N 0.000 description 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010025282 Lymphoedema Diseases 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 208000025584 Pericardial disease Diseases 0.000 description 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 208000035868 Vascular inflammations Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- YCKRFDGAMUMZLT-BJUDXGSMSA-N fluorine-18 atom Chemical compound [18F] YCKRFDGAMUMZLT-BJUDXGSMSA-N 0.000 description 1
- XGVXNTVBGYLJIR-UHFFFAOYSA-N fluoroiodomethane Chemical compound FCI XGVXNTVBGYLJIR-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 208000018578 heart valve disease Diseases 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000011630 iodine Chemical group 0.000 description 1
- PDJAZCSYYQODQF-UHFFFAOYSA-N iodine monofluoride Chemical compound IF PDJAZCSYYQODQF-UHFFFAOYSA-N 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 208000002502 lymphedema Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 230000002025 microglial effect Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- NZVKWLWAFUSDQE-UHFFFAOYSA-N n-[[2-(2-fluoroethoxy)-5-methoxyphenyl]methyl]-n-(5-fluoro-2-phenoxyphenyl)acetamide Chemical compound COC1=CC=C(OCCF)C(CN(C(C)=O)C=2C(=CC=C(F)C=2)OC=2C=CC=CC=2)=C1 NZVKWLWAFUSDQE-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- HJSQVJOROCIILI-UHFFFAOYSA-N ssr-180,575 Chemical compound O=C1C=2N(C)C3=CC(Cl)=CC=C3C=2C(CC(=O)N(C)C)=NN1C1=CC=CC=C1 HJSQVJOROCIILI-UHFFFAOYSA-N 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 201000002282 venous insufficiency Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07010701A EP1997515A1 (en) | 2007-05-30 | 2007-05-30 | Use of radiolabelled phenyloxyaniline derivatives for imaging diseases associated with peripheral benzodiazepin receptor's activation |
| PCT/EP2008/004042 WO2008145283A2 (en) | 2007-05-30 | 2008-05-21 | Use of radiolabelled phenyloxyaniline derivatives for imaging diseases associated with peripheral benzodiazepin receptor's activation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010528073A true JP2010528073A (ja) | 2010-08-19 |
| JP2010528073A5 JP2010528073A5 (https=) | 2011-07-07 |
Family
ID=38291288
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010509713A Withdrawn JP2010528073A (ja) | 2007-05-30 | 2008-05-21 | 循環器疾患を画像化するためのフェニルオキシアニリン誘導体の使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20100178248A1 (https=) |
| EP (2) | EP1997515A1 (https=) |
| JP (1) | JP2010528073A (https=) |
| AR (1) | AR066768A1 (https=) |
| CA (1) | CA2687729A1 (https=) |
| TW (1) | TW200914055A (https=) |
| WO (1) | WO2008145283A2 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016531155A (ja) * | 2013-09-13 | 2016-10-06 | バイオ イメージング コリア シーオー．，エルティーディー． | ［１８ｆ］フルオロメチル基が導入された脳神経炎症標的陽子放出断層撮影放射性追跡子、これらの合成及びそれを用いた生物学的結果の評価方法。 |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009298725A (ja) * | 2008-06-12 | 2009-12-24 | Natl Inst Of Radiological Sciences | 蛍光標識フェニルオキシアニリン誘導体及び蛍光標識プローブ |
| EP2181717A1 (en) * | 2008-10-28 | 2010-05-05 | Sanofi-Aventis | Use of 7-chloro-N,N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino[4,5-B]indole-1-acetamide as a biomarker of peripheral benzodiazepine receptor levels |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3997917B2 (ja) * | 2003-01-10 | 2007-10-24 | 株式会社デンソー | 地図検索装置 |
| CA2599321A1 (en) * | 2005-02-28 | 2006-09-08 | Taisho Pharmaceutical Co. Ltd. | Radioactive halogen-labeled phenyloxyaniline derivatives |
| WO2008114801A1 (en) * | 2007-03-12 | 2008-09-25 | National Institute Of Radiological Sciences | Pet visualization of amyloid-associated neuroinflammation in the brain |
-
2007
- 2007-05-30 EP EP07010701A patent/EP1997515A1/en not_active Withdrawn
-
2008
- 2008-05-21 JP JP2010509713A patent/JP2010528073A/ja not_active Withdrawn
- 2008-05-21 CA CA002687729A patent/CA2687729A1/en not_active Abandoned
- 2008-05-21 EP EP08758650A patent/EP2155263A2/en not_active Withdrawn
- 2008-05-21 US US12/602,238 patent/US20100178248A1/en not_active Abandoned
- 2008-05-21 WO PCT/EP2008/004042 patent/WO2008145283A2/en not_active Ceased
- 2008-05-29 TW TW097119789A patent/TW200914055A/zh unknown
- 2008-05-30 AR ARP080102269A patent/AR066768A1/es unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016531155A (ja) * | 2013-09-13 | 2016-10-06 | バイオ イメージング コリア シーオー．，エルティーディー． | ［１８ｆ］フルオロメチル基が導入された脳神経炎症標的陽子放出断層撮影放射性追跡子、これらの合成及びそれを用いた生物学的結果の評価方法。 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1997515A1 (en) | 2008-12-03 |
| TW200914055A (en) | 2009-04-01 |
| AR066768A1 (es) | 2009-09-09 |
| WO2008145283A3 (en) | 2009-09-03 |
| EP2155263A2 (en) | 2010-02-24 |
| CA2687729A1 (en) | 2008-12-04 |
| US20100178248A1 (en) | 2010-07-15 |
| WO2008145283A2 (en) | 2008-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2597425C2 (ru) | Соединения для связывания со специфическим для тромбоцитов гликопротеином iib/iiia и их применение для визуализации тромбов | |
| EA018650B1 (ru) | Daa-пиридин в качестве лиганда периферического бензодиазепинового рецептора для диагностической визуализации и фармацевтического лечения | |
| ES2643487T3 (es) | Compuestos para la utilización en la formación de imágenes, diagnóstico y/o tratamiento de enfermedades del sistema nervioso central o de tumores | |
| JP2011526267A (ja) | 化合物および放射性医薬品の製造方法 | |
| Franck et al. | Investigations into the synthesis, radiofluorination and conjugation of a new [18F] fluorocyclobutyl prosthetic group and its in vitro stability using a tyrosine model system | |
| TWI834874B (zh) | 對於食慾素-2受體拮抗劑之製備有用之方法及化合物、以及雜質少之萊博雷生 | |
| JP2012511527A (ja) | 陽電子放出アイソトープ標識のためのトリアリール−スルホニウム化合物、キット及び方法 | |
| Fuchigami et al. | Synthesis and evaluation of ethyleneoxylated and allyloxylated chalcone derivatives for imaging of amyloid β plaques by SPECT | |
| Vaidyanathan et al. | Synthesis and evaluation of 4-[18F] fluoropropoxy-3-iodobenzylguanidine ([18F] FPOIBG): A novel 18F-labeled analogue of MIBG | |
| JP2010528073A (ja) | 循環器疾患を画像化するためのフェニルオキシアニリン誘導体の使用 | |
| Lee et al. | Synthesis and evaluation of 6-(3-[18F] fluoro-2-hydroxypropyl)-substituted 2-pyridylbenzothiophenes and 2-pyridylbenzothiazoles as potential PET tracers for imaging Aβ plaques | |
| KR101315152B1 (ko) | 신규 유기화합물 및 상기 화합물을 이용한 방사성 할로겐표식 유기화합물의 제조 방법 | |
| JP7375755B2 (ja) | 陽電子放出核種で標識された脂肪酸誘導体 | |
| Hugenberg et al. | Synthesis, radiosynthesis, in vitro and first in vivo evaluation of a new matrix metalloproteinase inhibitor based on γ-fluorinated α-sulfonylaminohydroxamic acid | |
| KR102150377B1 (ko) | 플루오린-18이 치환된 피라졸 유도체 방사성의약품 제조방법 | |
| CN107406419B (zh) | Pet显像剂 | |
| EP2744776A1 (en) | New ligands for targeting of s1p receptors for in vivo imaging and treatment of diseases | |
| CN105593210B (zh) | 用于体内成像的咔唑化合物 | |
| US6362352B1 (en) | F18-labeled thia fatty acids and methods of making and using the same | |
| JP2016079108A (ja) | 放射性ヨウ素標識スチリル置換芳香族ヘテロ環化合物 | |
| WO2012025464A1 (en) | Fluorodeuteriomethyl tyrosine derivatives | |
| WO2026029180A1 (ja) | 放射性トリフェニルピラゾール化合物 | |
| CN109091681B (zh) | [18f]三氟甲基含硫氨基酸类pet显像剂及其制备方法和应用 | |
| JP2026023237A (ja) | １，４－ジアゼパン誘導体化合物及びｐｅｔプローブ | |
| JP6099045B2 (ja) | トリアゾロピリミジン誘導体化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110520 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110520 Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110520 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20120112 |